Navigation Links
Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
Date:9/17/2013

Oakland, CA (PRWEB) September 17, 2013

Dennis R. Hill, MD has confirmed today that he will be speaking to the American Cancer Society Man-to-Man support group on High Dose Rate Brachytherapy Tuesday, September 24, from 6:30 to 8:00pm at the Summit Campus of Alta Bates Summit Medical Center in Oakland, CA.

The Man to Man program helps men cope with prostate cancer by offering community-based education and support for patients and their family members. Part of this volunteer organization is outreach and collaboration with health care professionals. Dr. Hill has volunteered to speak for the second time in three years. His previous High Dose Rate Brachytherapy presentation was "a big hit" according to William H. Spurgeon the facilitator of the group. He also said, "We appreciate (Dr. Hill’s) time and energies to help educate our men."

Dr. Hill explains that High Dose Rate Brachytherapy is an advanced form of treatment for prostate cancer which treats the prostate with radiation from the inside out with temporary implanted catheters. It is less rigorous than surgery, less time consuming than external beam radiation, and more precise than permanent seed implant. The success rate is the same as surgery, external beam radiation and permanent seeds and there are fewer side effects according to Dr. Hill.

Dr. Hill has been doing High Dose Rate Brachytherapy exclusively since 2004. He has done over five hundred High Dose Rate Prostate Brachytherapy implants and has published scholarly articles on the subject.

His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA 94609 510-869-8875 drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11086490.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
2. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
3. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
4. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
5. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
6. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Discusses Prostate Cancer Stage vs. Gleason Score
7. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
8. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
9. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
10. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
11. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):